GlaxoSmithKline Historical Financial Ratios

GSK Stock

USD 38.52 0.21 0.55%

GlaxoSmithKline PLC is recently reporting on over 123 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 3.81 or Days Sales Outstanding of 50.76 will help investors to properly organize and evaluate GlaxoSmithKline PLC ADR financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Financial Ratios Analysis

GlaxoSmithKline PLC ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate GlaxoSmithKline PLC investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on GlaxoSmithKline financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across GlaxoSmithKline PLC history.

GlaxoSmithKline PLC Financial Ratios Chart

At this time, GlaxoSmithKline PLC's Sales General And Administrative To Revenue is quite stable compared to the past year. Capex To Operating Cash Flow is expected to rise to 0.48 this year, although the value of Days Sales Outstanding will most likely fall to 50.76.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Book Value Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing GlaxoSmithKline PLC ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on GlaxoSmithKline PLC sales, a figure that is much harder to manipulate than other GlaxoSmithKline PLC ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is GlaxoSmithKline PLC ADR dividend as a percentage of GlaxoSmithKline PLC stock price. GlaxoSmithKline PLC ADR dividend yield is a measure of GlaxoSmithKline PLC stock productivity, which can be interpreted as interest rate earned on an GlaxoSmithKline PLC investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most ratios from GlaxoSmithKline PLC's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

	2022	2023	2024	2025 (projected)
Dividend Yield	0.0599	0.0382	0.0445	0.0447
Price To Sales Ratio	1.97	1.94	1.75	1.66

Dividend Yield Price To Sales Ratio

GlaxoSmithKline PLC fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		-0.34	0.1	0.75	-0.39	-0.62	-0.65	0.69	0.1	1.0	-0.59	0.72	-0.72	-0.41	0.82	-0.85	0.89	-0.62	0.97	0.99	-0.07	0.77	1.0	0.99	-0.25	0.08
Dividend Yield	-0.34		-0.23	-0.17	0.02	0.3	0.33	-0.14	-0.23	-0.33	0.28	-0.32	0.42	0.18	-0.58	0.2	-0.36	0.4	-0.29	-0.35	0.46	-0.27	-0.35	-0.38	0.31	-0.23
Ptb Ratio	0.1	-0.23		0.28	0.24	-0.17	-0.1	0.19	1.0	0.11	-0.09	0.22	-0.03	0.28	0.08	-0.11	0.07	0.13	0.11	0.1	-0.24	0.1	0.08	0.09	-0.22	1.0
Days Sales Outstanding	0.75	-0.17	0.28		-0.42	-0.55	-0.54	0.38	0.28	0.75	-0.52	0.87	-0.6	0.11	0.54	-0.75	0.59	-0.24	0.8	0.76	-0.3	0.65	0.72	0.69	-0.52	0.3
Book Value Per Share	-0.39	0.02	0.24	-0.42		0.37	0.52	0.03	0.24	-0.38	0.42	-0.3	0.37	0.45	-0.34	0.24	-0.21	0.34	-0.39	-0.31	-0.32	-0.23	-0.34	-0.32	-0.19	0.24
Free Cash Flow Yield	-0.62	0.3	-0.17	-0.55	0.37		0.94	-0.28	-0.17	-0.61	0.98	-0.54	0.48	0.14	-0.63	0.38	-0.65	0.51	-0.75	-0.62	0.06	-0.89	-0.61	-0.61	0.23	-0.18
Operating Cash Flow Per Share	-0.65	0.33	-0.1	-0.54	0.52	0.94		-0.38	-0.1	-0.63	0.97	-0.6	0.49	0.21	-0.66	0.35	-0.6	0.55	-0.76	-0.65	0.11	-0.83	-0.64	-0.64	0.26	-0.11
Capex To Depreciation	0.69	-0.14	0.19	0.38	0.03	-0.28	-0.38		0.19	0.69	-0.32	0.46	-0.43	-0.21	0.56	-0.59	0.64	-0.37	0.65	0.72	-0.12	0.53	0.72	0.72	-0.22	0.17
Pb Ratio	0.1	-0.23	1.0	0.28	0.24	-0.17	-0.1	0.19		0.11	-0.09	0.22	-0.03	0.28	0.08	-0.11	0.07	0.13	0.11	0.1	-0.24	0.1	0.08	0.09	-0.22	1.0
Ev To Sales	1.0	-0.33	0.11	0.75	-0.38	-0.61	-0.63	0.69	0.11		-0.57	0.71	-0.72	-0.4	0.81	-0.86	0.89	-0.61	0.97	0.99	-0.07	0.76	0.99	0.99	-0.26	0.09
Free Cash Flow Per Share	-0.59	0.28	-0.09	-0.52	0.42	0.98	0.97	-0.32	-0.09	-0.57		-0.52	0.53	0.17	-0.66	0.36	-0.64	0.51	-0.72	-0.6	0.06	-0.88	-0.58	-0.59	0.22	-0.1
Roic	0.72	-0.32	0.22	0.87	-0.3	-0.54	-0.6	0.46	0.22	0.71	-0.52		-0.4	0.23	0.45	-0.59	0.47	-0.19	0.76	0.76	-0.54	0.57	0.7	0.67	-0.73	0.25
Inventory Turnover	-0.72	0.42	-0.03	-0.6	0.37	0.48	0.49	-0.43	-0.03	-0.72	0.53	-0.4		0.46	-0.91	0.85	-0.77	0.5	-0.71	-0.71	-0.03	-0.63	-0.73	-0.74	0.07	-0.01
Net Income Per Share	-0.41	0.18	0.28	0.11	0.45	0.14	0.21	-0.21	0.28	-0.4	0.17	0.23	0.46		-0.55	0.29	-0.49	0.69	-0.28	-0.32	-0.57	-0.18	-0.42	-0.44	-0.6	0.34
Days Of Inventory On Hand	0.82	-0.58	0.08	0.54	-0.34	-0.63	-0.66	0.56	0.08	0.81	-0.66	0.45	-0.91	-0.55		-0.75	0.88	-0.7	0.8	0.81	-0.05	0.76	0.84	0.86	-0.11	0.05
Payables Turnover	-0.85	0.2	-0.11	-0.75	0.24	0.38	0.35	-0.59	-0.11	-0.86	0.36	-0.59	0.85	0.29	-0.75		-0.8	0.33	-0.81	-0.84	0.01	-0.61	-0.85	-0.84	0.2	-0.09
Capex To Revenue	0.89	-0.36	0.07	0.59	-0.21	-0.65	-0.6	0.64	0.07	0.89	-0.64	0.47	-0.77	-0.49	0.88	-0.8		-0.63	0.88	0.89	0.03	0.86	0.91	0.92	-0.09	0.04
Cash Per Share	-0.62	0.4	0.13	-0.24	0.34	0.51	0.55	-0.37	0.13	-0.61	0.51	-0.19	0.5	0.69	-0.7	0.33	-0.63		-0.59	-0.6	-0.06	-0.55	-0.64	-0.65	-0.05	0.15
Pocfratio	0.97	-0.29	0.11	0.8	-0.39	-0.75	-0.76	0.65	0.11	0.97	-0.72	0.76	-0.71	-0.28	0.8	-0.81	0.88	-0.59		0.98	-0.11	0.87	0.97	0.96	-0.32	0.11
Interest Coverage	0.99	-0.35	0.1	0.76	-0.31	-0.62	-0.65	0.72	0.1	0.99	-0.6	0.76	-0.71	-0.32	0.81	-0.84	0.89	-0.6	0.98		-0.16	0.8	0.99	0.99	-0.34	0.09
Payout Ratio	-0.07	0.46	-0.24	-0.3	-0.32	0.06	0.11	-0.12	-0.24	-0.07	0.06	-0.54	-0.03	-0.57	-0.05	0.01	0.03	-0.06	-0.11	-0.16		-0.1	-0.09	-0.09	0.94	-0.29
Capex To Operating Cash Flow	0.77	-0.27	0.1	0.65	-0.23	-0.89	-0.83	0.53	0.1	0.76	-0.88	0.57	-0.63	-0.18	0.76	-0.61	0.86	-0.55	0.87	0.8	-0.1		0.79	0.79	-0.26	0.1
Pfcf Ratio	1.0	-0.35	0.08	0.72	-0.34	-0.61	-0.64	0.72	0.08	0.99	-0.58	0.7	-0.73	-0.42	0.84	-0.85	0.91	-0.64	0.97	0.99	-0.09	0.79		1.0	-0.26	0.06
Days Payables Outstanding	0.99	-0.38	0.09	0.69	-0.32	-0.61	-0.64	0.72	0.09	0.99	-0.59	0.67	-0.74	-0.44	0.86	-0.84	0.92	-0.65	0.96	0.99	-0.09	0.79	1.0		-0.24	0.07
Income Quality	-0.25	0.31	-0.22	-0.52	-0.19	0.23	0.26	-0.22	-0.22	-0.26	0.22	-0.73	0.07	-0.6	-0.11	0.2	-0.09	-0.05	-0.32	-0.34	0.94	-0.26	-0.26	-0.24		-0.28
Roe	0.08	-0.23	1.0	0.3	0.24	-0.18	-0.11	0.17	1.0	0.09	-0.1	0.25	-0.01	0.34	0.05	-0.09	0.04	0.15	0.11	0.09	-0.29	0.1	0.06	0.07	-0.28

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	1.58	1.52	1.97	1.94	1.75	1.66
Dividend Yield	0.0737	0.077	0.0599	0.0382	0.0445	0.0447
Ptb Ratio	3.7	3.45	5.46	4.4	4.02	3.81
Days Sales Outstanding	59.4	66.83	67.86	71.07	63.96	50.76
Book Value Per Share	5.23	6.66	2.51	3.16	3.21	3.37
Operating Cash Flow Per Share	2.03	2.12	2.48	1.84	1.61	0.89
Stock Based Compensation To Revenue	0.0117	0.0108	0.009883	0.0101	0.0118	0.0084
Capex To Depreciation	0.72	3.59	1.16	0.98	1.17	1.55
Pb Ratio	3.7	3.45	5.46	4.4	4.02	3.81
Ev To Sales	2.87	2.19	2.11	2.56	2.43	2.06
Free Cash Flow Per Share	1.56	1.57	1.28	1.09	0.88	0.62
Roic	0.0942	0.12	0.0984	0.14	0.0851	0.0808
Net Income Per Share	1.17	1.44	1.37	1.22	0.63	0.6
Days Of Inventory On Hand	186.99	181.92	196.6	234.3	228.69	217.39
Payables Turnover	2.69	2.56	2.47	2.3	2.61	3.99
Capex To Revenue	0.0657	0.0859	0.077	0.0773	0.095	0.0813
Cash Per Share	1.21	1.6	1.35	1.96	0.91	0.69
Pocfratio	6.39	6.54	7.82	8.68	8.38	7.96
Interest Coverage	8.73	7.91	7.32	8.7	6.28	5.97
Payout Ratio	0.85	0.69	0.91	0.7	0.95	0.82
Pfcf Ratio	8.7	10.35	11.25	13.28	15.37	14.6
Days Payables Outstanding	135.88	142.66	147.7	158.4	139.66	172.0
Income Quality	1.32	1.56	1.5	1.37	2.22	2.33
Ev To Operating Cash Flow	8.86	9.04	10.15	10.91	10.4	9.88
Pe Ratio	9.39	11.85	11.76	11.92	21.32	27.57
Return On Tangible Assets	0.12	0.14	0.11	0.13	0.0697	0.0662
Ev To Free Cash Flow	12.06	14.31	14.6	16.69	19.09	18.14
Earnings Yield	0.11	0.0844	0.085	0.0839	0.0469	0.045
Intangibles To Total Assets	0.52	0.5	0.51	0.36	0.37	0.38
Net Debt To E B I T D A	2.05	2.57	2.0	1.65	1.99	2.09
Current Ratio	0.75	0.81	0.91	0.79	0.78	1.49
Tangible Book Value Per Share	(4.93)	(6.02)	(2.8)	(2.17)	(2.31)	(2.19)
Graham Number	10.91	12.03	8.51	9.49	6.9	3.87

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.173

Dividend Share

0.61

Earnings Share

1.6

Revenue Per Share

15.392

Quarterly Revenue Growth

0.008

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

GlaxoSmithKline Historical Financial Ratios

About GlaxoSmithKline Financial Ratios Analysis

GlaxoSmithKline PLC Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Book Value Per Share

GlaxoSmithKline PLC fundamentals Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pfcf Ratio	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Roe	+ 1.0	Ptb Ratio
Roe	+ 1.0	Pb Ratio
Days Payables Outstanding	+ 1.0	Pfcf Ratio

Days Of Inventory On Hand	- 0.91	Inventory Turnover
Capex To Operating Cash Flow	- 0.89	Free Cash Flow Yield
Capex To Operating Cash Flow	- 0.88	Free Cash Flow Per Share
Payables Turnover	- 0.86	Ev To Sales
Pfcf Ratio	- 0.85	Payables Turnover
Payables Turnover	- 0.85	Price To Sales Ratio